# Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

> **NCT06815029** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Recurrent Astrocytoma, IDH-Mutant, Grade 3
- Recurrent Astrocytoma, IDH-Mutant, Grade 4
- Recurrent Glioblastoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Chimeric Antigen Receptor T-Cell Therapy
- **PROCEDURE:** Echocardiography
- **OTHER:** Fludeoxyglucose F-18
- **PROCEDURE:** Intracranial Catheter Placement
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Resection

## Key facts

- **NCT ID:** NCT06815029
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2030-10-11
- **Final completion:** 2030-10-11
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06815029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06815029, "Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06815029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*